association

Full identifier: http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association

Assigned to 1 class:

Minted in Nanopublication

 RAL6CgExAu comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAL6CgExAu... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T14:55:22.169+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAL6CgExAu... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAL6CgExAu... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAL6CgExAu... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
benlysta belimumab is indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus sle who are receiving standard therapy limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations benlysta is a b lymphocyte stimulator blys specific inhibitor indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus who are receiving standard therapy 1 limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations 1
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:55:22.169Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)